source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…Endpoints · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and morePeople on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipatedSTAT · 3mo ago↗ source
- The connection between periods and mental healthPlans to oust Makary, a looming Supreme Court deadline on mifepristone, and other health news from Morning RoundsSTAT · 3mo ago